GLSI vs GNTA

Greenwich LifeSciences, Inc. vs Genenta Science S.p.A. — Valuation Comparison 2026

GLSI

Biotechnology
Greenwich LifeSciences, Inc.
Quality
4.0
out of 10
Value Trap
Price
$28.99
Last close
Models
6/13
Active
VS

GNTA

Biotechnology
Genenta Science S.p.A.
Quality
4.7
out of 10
Value Trap
12
SAFE
Price
$0.90
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType GLSI Fair ValueGLSI Upside GNTA Fair ValueGNTA Upside
Bayesian DCF Intrinsic $7.90 -72.7% $0.30 -66.6%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $0.58 -98.0% $0.80 -11.1%
PWERM Option-Based $27.15 -6.3% $0.87 -3.3%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for GLSI vs GNTA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

GLSI vs GNTA — Which Stock Is More Undervalued?

GNTA scores higher with a 4.7/10 quality rating vs GLSI's 4.0/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Greenwich LifeSciences, Inc. (GLSI) and Genenta Science S.p.A. (GNTA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

GLSI currently trades at $28.99 with a QOC of 4.0/10, while GNTA trades at $0.90 with a QOC of 4.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).